Live news related to IPSEN stock (FR0010259150): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
Ipsen announced on Tuesday the results of the phase IV DIRECTION study, the first direct double-blind comparison between its products Dysport and Boto…
The biopharmaceutical company regains momentum this Tuesday mid-session, after a nearly 5% drop the previous day. The stock is priced at €158.70, in a…
The biopharmaceutical company fell sharply this Monday mid-session, among the steepest declines in the SBF 120. The stock fell to €158.10, below its 2…
Ipsen announced the resignation of Karen Witts from her role as a board member, effective after the Annual General Meeting on May 13, 2026. Having ser…
Ipsen announced on Thursday the presentation of Phase II data for corabotase, an experimental molecule classified as the first of a new therapeutic cl…
Ipsen significantly advanced this Thursday, April 23, driven by the announcement of a first-quarter revenue increase of 22.6% at constant exchange rat…
Ipsen reported on Thursday, April 23, a first-quarter 2026 revenue of EUR 1,074.9 million, up 22.6% at constant exchange rates. This growth, which exc…
This Wednesday afternoon, Ipsen marks one of the best performances on the SBF 120 in a slightly declining Parisian market. The French biopharmaceutica…
The European Commission has granted conditional marketing authorization to Ipsen's Ojemda (tovorafenib) for treating children with pediatric low-grade…
The share of the French pharmaceutical company is trading at €169.40 this Friday, up 4.12% from the previous day, reaching a new all-time high in the …
